



Hemke, A. C., Heemskerk, M., van Diepen, M., Kramer, A., De Meester, J., Heaf, J. G., & Caskey, F. (2018). Performance of an easy-to-use prediction model for renal patient survival: an external validation study using data from the ERA-EDTA Registry . *Nephrology Dialysis Transplantation*, 33(10), 1786-1793. [gfx348]. <https://doi.org/10.1093/ndt/gfx348>

Peer reviewed version

License (if available):
Unspecified

Link to published version (if available):
[10.1093/ndt/gfx348](https://doi.org/10.1093/ndt/gfx348)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Oxford University Press at <https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfx348/4812040> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/pure/about/ebr-terms>

Performance of an easy to use prediction model for renal patient survival: an external validation study using data from the ERA-EDTA Registry

Mrs. Aline C. Hemke, MSc, Dutch Transplant Foundation, Organ Centre, Leiden, the Netherlands, Dutch Renal Replacement Registry, Leiden, the Netherlands, a.hemke@transplantatiestichting.nl

Martin B.A. Heemskerk PhD, Dutch Transplant Foundation, Organ Centre, Leiden, the Netherlands, m.heemskerk@transplantatiestichting.nl

Merel van Diepen PhD, Leiden University Medical Centre, Clinical Epidemiology, Leiden, the Netherlands, M.van_Diepen@lumc.nl

Anneke Kramer, PhD, Academic Medical Center, University of Amsterdam, Amsterdam Public Health research institute, Department of Medical Informatics, ERA-EDTA Registry, Amsterdam, the Netherlands, a.kramer@amc.uva.nl

Johan de Meester, PhD, AZ Nikolaas, Department of Nephrology, Dialysis, and Hypertension, Sint-Niklaas, Belgium, johan.DeMeester@aznikolaas.be

James G. Heaf, MD DMSc, Zealand University Hospital, Department of Medicine, Roskilde, Denmark, d110582@dadlnet.dk

José Maria Abad Diez, PhD, Aragon Renal Registry, Planning Department, Aragon health Service Spain, jmabad@aragon.es

Marta Torres Guinea, PhD, Hospital Virgen de La Salud, Department of Nephrology, Toledo, Spain, martat@sescam.iccm.es

Patrik Finne, PhD, Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Finland and Finnish Registry for Kidney Diseases, Helsinki, Finland, patrik.finne@helsinki.fi

Philippe Brunet, PhD, Aix Marseille Univ, APHM, Hospital de la Conception, Centre de Nephrologie et Transplantation renale, Marseille, France, drphilippe.brunet@outlook.com

Bjørn E. Vikse, Haugesund, PhD, Department of Medicine, Haugesund, Haugesund, Norway and Department of Clinical Medicine, University of Bergen, Bergen, Norway. bnev@helse-sonna.no

Fergus J. Caskey, PhD, UK Renal Registry, Southmead Hospital, Bristol, United Kingdom and University of Bristol, School of Social and Community Medicine, Canynge Hall, Bristol, United Kingdom, fjcaskey@doctors.org.uk

Jamie P. Traynor, MD, The Scottish Renal Registry, Information Services Division Scotland, Glasgow, United Kingdom, Jamie.traynor@nhs.net

Ziad A. Massy, MD. PhD, Division of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, Paris, France, and Institut National de la Santé et de la Recherche Médicinale (INSERM) U1018 team5, Research Centre in Epidemiology and Population Health (CESP), University of Paris Ouest-Versailles-St Quentin-en-Yveline, Villejuif, France, ziad.massy@aphp.fr

Cécile Couchoud, PhD, Renal Epidemiology and information Network (REIN) Registry, French Biomedical Agency, Saint-Denis-la-Plaine, France, cecile.couchoud@biomedecine.fr

Jaap W. Groothoff, PhD, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands, j.w.groothoff@amc.uva.nl

Maurizio Nordio MSc(Epid), Veneto Dialysis and Transplantation Registry, Regional Epidemiology System, Padua, Italy and Nephrology and Dialysis Unit, AULSS 6, Padua, Italy, maurizio.nordio@gmail.com

Kitty J. Jager, PhD, Academic Medical Center, University of Amsterdam, Amsterdam Public Health research institute, Department of Medical Informatics, ERA-EDTA Registry, Amsterdam, the Netherlands, k.j.jager@amc.uva.nl

Friedo W. Dekker, PhD, Leiden University Medical Centre, Clinical Epidemiology, Leiden, the Netherlands, F.W.Dekker@lumc.nl

Andries J. Hoitsma, PhD, University Medical Centre Nijmegen, Nephrology, Nijmegen, the Netherlands, Dutch Transplant Foundation, Organ Centre, Leiden, the Netherlands, aj.hoitsma@transplantatiestichting.nl

ALL AUTHORS HAVE NO CONFLICT OF INTEREST REGARDING THIS MANUSCRIPT

Abstract

Background

An easy to use prediction model for long-term renal patient survival, based on only four predictors (age, primary renal disease, sex, and therapy at 90 days after the start of renal replacement therapy (RRT)), has been developed in the Netherlands. To assess the usability of this model for use in Europe, we externally validated the model in ten European countries.

Methods

Data from the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) Registry were used. Ten countries that reported individual patient data to the registry on patients starting RRT in the period of 1995-2005 were included. Patients under 16 years of age and/or with missing predictor variable data were excluded. The external validation of the prediction model was evaluated for the 10-year (primary endpoint), 5- and 3-year survival predictions by assessing the calibration and discrimination outcomes.

Results

We used a dataset of 136,304 patients from 10 countries. The calibration in the large and calibration plots for 10 deciles of predicted survival probabilities showed average differences of 1.5%, 3.2% and 3.4% in observed versus predicted 10-, 5-, and 3-year survival, with some small variation on country-level. The C-index, indicating the discriminatory power of the model, was 0.71 in the complete ERA-EDTA Registry cohort and varied according to country level between 0.70 and 0.75.

Conclusions

A prediction model for long-term renal patient survival developed in a single country, based on only four easily available variables, has a comparably adequate performance in a wide range of other European countries.

Introduction

End stage renal disease (ESRD) is a major health problem with high mortality rates, affecting approximately 1000 patients per million population (pmp) in European countries¹. The overall yearly unadjusted incidence of new ESRD patients starting renal replacement therapy (RRT) is over 100 patients pmp.

For nephrologists it could be helpful to be able to predict long-term survival chances for all patients starting with RRT to support initial patient counseling. As it is unclear at therapy initiation whether a patient will stay on dialysis or subsequently receive a kidney transplant, it is desirable to use a model for overall survival prediction after the start of RRT, irrespective of treatment. Most existing prediction models are focused on dialysis survival until transplantation², survival on the kidney transplant waiting list^{3,4} or patient survival after renal transplantation^{5,6}, or are designed for a specific patient group⁷, and therefore cannot be used for overall RRT survival prediction. In 2013, a straightforward model to predict renal patient survival from the start of RRT was developed, based on a cohort of incident RRT patients from 1995-2005 in the Netherlands⁸. It predicts 10-year survival based on four commonly available predictors: age at the start of RRT, sex, primary renal disease (PRD), and mode of renal replacement therapy at 90 days (hemodialysis (HD), peritoneal dialysis (PD), or transplantation). Unlike the existing models, this model predicts overall survival from the start of RRT, irrespective of whether patients will change treatment modality in a later stage or not.

A general survival prediction model is desirable for patients to understand the survival implications of ESRD and it can be used for shared patient-physician discussion of future treatment perspectives, like the consideration of conservative care as an alternative for starting dialysis. Furthermore, a survival prediction model could be useful in research for patient selection, group comparisons, or for patient stratification according to survival risk in clinical trials. Although for individual patient survival predictions it is preferable to take additional clinical parameters into account if available, as concluded in a later study⁹, we think that the original straightforward registry model might be very valuable for group comparisons in studies, countries, or in periods of time, and for risk stratification or selection purposes in (etiologic) studies. Therefore this study has been performed.

In order to understand whether this prediction model developed in a patient group from one country is also suitable for use in other countries, it is essential to explore its generalizability in an external validation study¹⁰. The predictive performance of the model in the Netherlands appeared to be adequate, as demonstrated by internal validation outcomes (good calibration results as well as discrimination (C-index: 0.720))⁸. However, internal validation merely relates to the “reproducibility” of results, while the usability of the prediction model in another country is a question of “transportability” of the model¹¹. As countries differ in dialysis and transplantation possibilities (e.g. access to (home) dialysis, and possibility for renal transplantation (with a living or deceased donor)) as well as in patient population characteristics, this could influence survival prediction. In this external validation study, we therefore assessed the performance of the model as a European renal patient survival prediction model, using data from the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry.

Subjects and methods

We used ERA-EDTA Registry data from ten European countries with national or regional registries providing individual level patient data on patients who started RRT between 1995 and 2005. Like in the original model, 90 days after the start of RRT was used as baseline, to exclude acute patients and to ensure enough time to switch to the intended therapy modality. We included last available follow-up information in the ERA-EDTA Registry until 1/1/2014. We excluded the country where the model was developed (the Netherlands) and countries with less than 1000 incident patients in our period of interest. The remaining countries that were included in the validation study are: Austria, Belgium (data from the Dutch-speaking and French-speaking Belgian Registry), Denmark, Spain (data from the regional registries of Andalusia, Aragon, Asturias, Basque country, Catalonia, Cantabria, Castile and León, Castile-La Mancha, Extremadura, Valencia), Finland, France, Greece, Norway, Sweden, and the United Kingdom (data from the UK Renal Registry and the Scottish Renal Registry). Most countries had 100% completeness in the whole study period, with the exception of Spain (coverage increasing from 53% in 1995 to 68% in 2005), France (coverage increasing from 17% in 2002 to 55% in 2005), and the UK (coverage increasing from 9% in 1995 to 89% in 2005). We included the patients that were at least 16 years old at the start of RRT. We excluded patients that stopped renal replacement therapy within 3 months after the start of RRT, including patient death, (N=96, 0.07%) and patients with missing values on one or more of the remaining prediction variables (833 patients with missing PRD, 0.6%). The events from 90 days after the start of RRT till death or end of the study were analyzed (1/1/2014); the follow-up period was maximized at 10 years. This resulted in a dataset of 136,304 patients.

The original model⁸ was developed to predict 10-year patient survival from 90 days after the start of RRT. It was based on age at the start of RRT, primary renal disease (PRD), sex, and therapy at 90 days. The formula for the survival probability at time t , $S(t)$, is $S(t)=\exp(-H(t))$. Here $H(t)$ is the cumulative hazard that is calculated from the baseline hazard (H_0) as $H(t)=H_0(t)*\exp(\text{prognostic index})$. The prognostic index can be calculated, using the values of the four predictors for a specific patient (see table 1) together with their parameter estimates. The primary endpoint of interest was 10-year survival; additionally we evaluated the performance of the model for 5 and 3-year survival.

We analyzed the performance of the model both in the total ERA-EDTA Registry cohort, as well as in the separate countries (anonymously). In order to be transparent and enhance the usability of the model, we followed the recently published TRIPOD checklist^{12;13}. In table 1 we therefore provide the renal patient survival prediction model which was also published in BMC Nephrology 2013⁸. The performance of the prediction model was evaluated by assessing both calibration and discrimination. Calibration is the agreement between the probability of developing the outcome of interest within a certain time period (in our case 10-, 5- and 3-year survival) as estimated by the model and the observed outcome frequencies¹⁴. Measures to represent calibration in our study are the calibration in the large, calibration plots and calibration slopes. "Calibration in the large" is the overall calibration, measured as the observed versus

predicted survival for the complete patient cohort. The calibration plot is a graphical method to express calibration, by plotting the observed outcome frequencies against the mean predicted outcome probabilities, within subgroups of participants that are ranked by increasing estimated survival probability¹⁴. Ideally the plots follow a 45 degree line, with an intercept of 0 and a slope of 1¹⁵. This is also reflected in the calibration slope, which represents the outcome of a Cox regression analysis with the prognostic (risk) index as the only predictor¹⁵ and is thus ideally equal to 1. Discrimination is the ability of a model to distinguish individuals who experience the outcome from those who remain event free¹⁴. The concordance index (C-index) is the most widely used measure to evaluate discrimination. For a Cox model it represents the chance that, given two individuals, the model assigns a higher risk score to the one that develops the event of interest in the shortest period of time. A C-index of 0.5 indicates no discriminative power and a C-index of 1 indicates perfect discriminative power¹⁶. A C-index of 0.7 is considered reasonable and a C-index of 0.8 is considered good.

Because age is a strong predictor for survival, we performed an additional sensitivity analysis, stratifying calibration and discrimination analyses by age. For comparison of model performance we also stratified by sex. Further, as some countries only had good data completeness in more recent years, we stratified the calibration and discrimination analysis by starting year of renal replacement therapy.

Results

The distribution of the prediction model variables (age at the start of RRT, sex, primary renal disease (PRD) and the therapy at 90 days) over the 10 European countries that are used in our external validation study are shown in table 2. Most variation between countries as well as between validation and development cohort is seen in the distribution of PRD and therapy at 90 days.

The calibration in the large for the prediction model in the ERA-EDTA Registry cohort show adequate results, with a difference of 1.5%, 3.2% and 3.4% in observed versus predicted 10-, 5- and 3-year overall RRT survival respectively. The calibration plots for 10 deciles of predicted survival for 10-, 5- and 3-year survival are shown in Figure 1.

The calibration results of the prediction model at the country level show varying results; in 5 countries (countries 1-5) the observed and predicted survival probabilities are similar with an overall difference of $\leq 1\%$ (Figure 2), so the performance of the original model is good. In the other 5 countries the predicted survival probabilities are either slightly higher (country 8) or slightly lower (countries 6, 7, 9, and 10). The average absolute difference between observed and predicted survival over the countries is 3% (0-8%) for 10-year survival, and 4% (0-9%) for 5- and 3-year survival.

The calibration slope, with the prognostic index as the only predictor, is 0.995 for the complete ERA-EDTA Registry cohort. For the separate countries the slopes differ from 0.922 till 1.088, which is close to the ideal 1.

The discrimination for 10-year survival, expressed as the C-index, shows adequate performance of the model, with values between 0.70 and 0.75 (Figure 3) for the 10 different countries and 0.710 (95% CI: 0.708-0.712) for the complete ERA-EDTA Registry cohort.

Stratified calibration and discrimination results (Table 3) show that within the different age groups discrimination was moderate. Discrimination was best in the patients aged younger than 65, and 10 year calibration was best for the oldest age categories. Model performance in the different sexes is similar. Further this stratified sensitivity analysis shows that model performance slightly deteriorated in time.

Discussion

With this study we examined the external validity of a previously published renal patient survival prediction model based on four commonly available variables. The model performance in ten European countries reporting to the ERA-EDTA Registry is adequate, with an overall C-index of 0.71 and an average 10-year calibration difference of 1.5%. The model performance for the long term survival prediction is slightly better than the short term survival prediction, as could be expected as the model has been developed for 10-year survival. Although age is the strongest predictor, the model still performs well within the youngest age strata (below 65 years of age). This indicates that the other three predictors add discriminating value. The fact that these external validation outcomes are similar to the internal validation results in the country where the model was developed indicates the robustness of the model.

These external validation outcomes are remarkable, taking into account the many differences between European countries in ESRD patient characteristics and treatment^{1;17-21}, as well as mortality rates on dialysis²². If the model would be influenced by differences in the standard of care between countries, such as differences in the percentage of living donor transplants, quality of donated kidneys, or patients starting RRT at earlier stages of disease, this would directly be reflected by significant difference in outcome. On the other hand, if differences are a consequence of population differences that are either directly or indirectly covered by the model, it will not impact model performance.

The model corrects for differences in patient age, sex, PRD and therapy at 90 days after the start of RRT, as these are part of the prediction model. Indirectly the model probably also partly corrects for differences in patient condition, as some of the model variables (like PRD, therapy and age) are related to patient condition (e.g. hypertension, BMI and cardiovascular disease). Next to clinical variation, there are other differences that might affect ESRD patient care and survival such as, human and environmental factors (dietary habits²³, smoking, physical activity²⁴, socioeconomic status²⁵ and birth weight²⁶, healthcare policies²⁷ and genetic differences²⁸) and access to the waiting list and renal transplantation. Stel et al.²⁹ conclude from a study in four European countries that variation in transplantation rates may be due to a combination of factors, including legislation, donor availability, transplantation system organization and infrastructure, wealth and investment in health care, as well as underlying public attitudes/awareness to donation and transplantation. The fact that reimbursement strategies play a role has been confirmed by a study among 5 European countries, the United States and

Canada³⁰. Finally, Kramer et al. have shown that macroeconomic factors as well as the intrinsic mortality of the dialysis population are associated with differences in the mortality on dialysis between countries²². Nevertheless, despite the fact that there probably are factors that influence renal patient care and the mortality on RRT, which are not covered by the model, we have shown that the renal patient survival prediction model is applicable in a wide range of countries. The many differences of the ERA-EDTA Registry cohort compared to the Dutch model development cohort actually makes it a very suitable data set for external validation, which in itself is a major strength of this study.

Our validation study shows a comparably sufficient but moderate discriminative power (C-index: 0.71) of the prediction model in other European countries as was also the case in the Dutch cohort⁸. This indicates that there is room for improvement. In 2013 we showed, based on data from the Netherlands Cooperative Study on Adequacy of Dialysis treatment (NECOSAD) how the original survival prediction model could be improved by adding more clinical data⁹. Especially the reclassifications at patient level implied that individual survival probability is influenced substantially by the clinical condition of the patient, so an extended model is preferably used for individual survival prediction, as an objective predicted survival estimator, next to expert opinion. However, as many countries do not register the required additional data on a regular basis yet, it is not possible to externally validate an extended prediction model in a wide spectrum of European countries. This may be different in the future. Although the validated model is less suitable to be used to predict individual patient survival, the validated renal patient survival model can be used by European countries to predict objective survival chances for groups of patients, to compare risk groups in different studies, or for risk stratification/selection. For example, the model can be used to select patients with a predicted 10-year mortality risk over 60% to participate in a study, or the model can be used to demonstrate time trends in the incident patient populations in a country by differentiation on risk group (defined by specified ranges of mortality rates). As has been pointed out in the two manuscripts describing the previous models, it is important to note that the model is not recommended for basing clinical treatment decisions^{8,9}, as prediction models do not prove causality, and the predictor “treatment at 90 days” is merely a proxy for patient condition.

The strength of this study is the validation of the renal patient survival model in ten different European countries, with good or acceptable results in all of these countries. Since we observed some variation at country-level, this study also stresses the importance of external model validation in more than just one country. External validation limited to one single country could lead to over- or underestimated model performance, when the mortality rate in this population is different from the reference population^{10:31}. Based on our aim to externally validate the original prediction model, we have evaluated this model without any adjustments. Our validation results show good discrimination, and only slightly inferior calibration outcomes in some countries. Therefore in our opinion, model adjustment was not necessary. However, when the presented prediction model is used in another population with differing mortality rates resulting in inadequate calibration results, it would be recommended to recalibrate the model by adjusting the baseline hazard, using actual population data, as described by Toll et al.³². In fact, a purpose of future research could be to update the model based on European data to optimize performance in this population and to establish a European model, possibly even with country

as a predictor on top of the four predictors currently used. This might further increase the usefulness of the RRT survival prediction model in other European countries. Depending on the proposed use of the new model, it might also be considered to develop a risk chart to estimate survival chances for different risk groups. In either case external validation of the newly developed model is needed again.

Despite the fact that the prediction model has shown to be valuable in this external validation cohort, there are still some study weaknesses to be noted. The most important limitation of the study is that the model has only been validated in other countries, but not in another period of time. In our study this was not possible, since a more recent cohort does not have 10 years of follow-up yet. However, knowing that RRT population and treatment possibilities as well as treatment quality and survival²¹ change over time, regular evaluation, and possible recalibration (as suggested earlier for other populations), of the model is recommended. A second limitation of this study is that for some countries we validated our results on patients from only a limited number of years or from a limited number of regions, which might introduce selection bias and influence calibration and discrimination outcomes. Although that might introduce differences at country level, we don't think that this changes the conclusions of the validation study. In fact model performance might be slightly underestimated in these countries, and for the complete ERA-EDTA Registry cohort, as model performance is more likely to deteriorate in other periods of time, as pointed out in the previous limitation, and confirmed by the results of the analyses stratified by time. Finally we should mention the fact that the model uses mainly very straightforward variables, except for the PRD. There might be difficulties to adequately (and uniformly) describe the patient's disease. However, the PRD with the most influence on survival (diabetes) is relatively easy to detect.

In conclusion, our external validation study shows that a straightforward prediction model for long term patient survival on RRT developed in a single country, based on only four easily available variables, has a comparably adequate performance in a wide range of European countries participating in the ERA-EDTA Registry.

Acknowledgements

We would like to thank the patients and the staff of dialysis and transplant units for contributing the data via their national and regional renal registries. We also would like to thank the following registries for the contribution of these data: Austrian Dialysis and Transplant Registry [OEDTR] (R. Kramar); Dutch speaking Belgian Society of Nephrology [NBVN] (B. De Moor and F. Schroven,); French speaking Belgian Society of Nephrology [GNFB] (JM. des Grottes and F. Collart); Danish Nephrology Registry [DNS]; Finnish Registry for Kidney Diseases (C. Grönhagen-Riska); The Epidemiology and Information Network in Nephrology [REIN] (M. Lassalle); Greek Renal Registry (N. Afentakis); Norwegian Renal Registry (T. Leivestad); Swedish Renal Registry [SNR] (K.G. Prütz, M. Stendahl, M. Evans, S. Schön, L. Bäckman, and M. Segelmark); Dutch End-Stage Renal Disease Registry [RENINE] (M. Hemmelder); UK Renal Registry (All the staff of the UK Renal Registry and of the renal units submitting data); Scottish Renal Registry [SRR] (All of the Scottish renal units); and the regional registries of Andalusia

[SICATA] (P. Castro de la Nuez), Aragon (J.I. Sanchez Miret), Asturias (R. Alonso de la Torre, J.R. Quirós, and RERCA Working Group), Basque country [UNIPAR] (Á. Magaz, J. Aranzabal, M. Rodrigo, and I. Moina), Cantabria (M. Arias Rodríguez and O. García Ruiz), Castile and León (R. González and C. Fernández-Renedo), Castile-La Mancha (G. Gutiérrez Ávila and I. Moreno Alía), Catalonia [RMRC] (E. Arcos, J. Comas, and J. Tort), Extremadura (J.M. Ramos Aceitero and M.A. García Bazaga), and Valencian region [REMRENAL] (O. Zurriaga Llorens, M. Ferrer Alamar, and N. Fuster Camarena); and the other ERA-EDTA Registry committee members for their advice in the analysis and the drafting of this paper: A. Więcek, M. Evans, J. Harambat, F. Jarraya, and I. Rychlik; and M. Pippias, and V.S. Stel in the AMC Registry office for data collection and management. The ERA-EDTA Registry is funded by the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). This article was written by A.C. Hemke, M.B.A. Heemskerk, M. van Diepen, A. Kramer, J. de Meester, J.G. Heaf, J.M. Abad Diez, M. Torres Guinea, P. Finne, P. Brunet, B.E. Vikse, F.J. Caskey, J.P. Traynor, Z. Massy, C. Couchoud, J.W. Groothoff, M. Nordio, K.J. Jager, F.W. Dekker, and A.J. Hoitsma on behalf of the ERA-EDTA Registry which is an official body of the ERA-EDTA (European Renal Association – European Dialysis and Transplant Association).

Transparency declarations

None to declare.

Authors' contributions

All authors have contributed to the results of this paper.

A. Hemke, M. Heemskerk, M. van Diepen and A. Kramer have worked on the design, analysis and interpretation of the data, and the other authors have worked on the design and interpretation of the data. All authors have worked on drafting/revising the article, providing intellectual content and final approval of the version to be published.

Reference List

1. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2013. Academic Medical Centre, Department of Medical Informatics, Amsterdam, The Netherlands. 2015.
Ref Type: Report
2. Wagner M, Ansell D, Kent DM et al. Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. *Am J Kidney Dis* 2011; 57: 894-902
3. van Walraven C, Austin PC, Knoll G. Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease. *CMAJ* 2010; 182: 666-672
4. Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? *Clin J Am Soc Nephrol* 2006; 1: 532-538

5. Jassal SV, Schaubel DE, Fenton SS. Predicting mortality after kidney transplantation: a clinical tool. *Transpl Int* 2005; 18: 1248-1257
6. Kasiske BL, Israni AK, Snyder JJ, Skeans MA, Peng Y, Weinhandl ED. A simple tool to predict outcomes after kidney transplant. *Am J Kidney Dis* 2010; 56: 947-960
7. Couchoud CG, Beuscart JB, Aldigier JC, Brunet PJ, Moranne OP. Development of a risk stratification algorithm to improve patient-centered care and decision making for incident elderly patients with end-stage renal disease. *Kidney Int* 2015; 88: 1178-1186
8. Hemke AC, Heemskerk MB, van DM, Weimar W, Dekker FW, Hoitsma AJ. Survival prognosis after the start of a renal replacement therapy in the Netherlands: a retrospective cohort study. *BMC Nephrol* 2013; 14: 258
9. Hemke AC, Heemskerk MB, van DM, Dekker FW, Hoitsma AJ. Improved Mortality Prediction in Dialysis Patients Using Specific Clinical and Laboratory Data. *Am J Nephrol* 2015; 42: 158-167
10. Moons KG, Kengne AP, Grobbee DE et al. Risk prediction models: II. External validation, model updating, and impact assessment. *Heart* 2012; 98: 691-698
11. Nieboer D, van der Ploeg T, Steyerberg EW. Assessing Discriminative Performance at External Validation of Clinical Prediction Models. *PLoS One* 2016; 11: e0148820
12. Moons KG, Altman DG, Reitsma JB, Collins GS. New Guideline for the Reporting of Studies Developing, Validating, or Updating a Multivariable Clinical Prediction Model: The TRIPOD Statement. *Adv Anat Pathol* 2015; 22: 303-305
13. Tangri N, Kent DM. Toward a modern era in clinical prediction: the TRIPOD statement for reporting prediction models. *Am J Kidney Dis* 2015; 65: 530-533
14. Moons KG, Kengne AP, Woodward M et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. *Heart* 2012; 98: 683-690
15. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. *Eur Heart J* 2014; 35: 1925-1931
16. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med* 1996; 15: 361-387
17. Bruck K, Stel VS, Gambaro G et al. CKD Prevalence Varies across the European General Population. *J Am Soc Nephrol* 2016; 27: 2135-2147
18. Pippias M, Jager KJ, Kramer A et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. *Nephrol Dial Transplant* 2016; 31: 831-841
19. Noordzij M, Kramer A, Abad Diez JM et al. Renal replacement therapy in Europe: a summary of the 2011 ERA-EDTA Registry Annual Report. *Clin Kidney J* 2014; 7: 227-238
20. van de Luijngaarden MW, Jager KJ, Segelmark M et al. Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period. *Nephrol Dial Transplant* 2016; 31: 120-128

21. Kramer A, Stel V, Zoccali C et al. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. *Nephrol Dial Transplant* 2009; 24: 3557-3566
22. Kramer A, Stel VS, Caskey FJ et al. Exploring the association between macroeconomic indicators and dialysis mortality. *Clin J Am Soc Nephrol* 2012; 7: 1655-1663
23. Nothlings U, Boeing H, Maskarinec G et al. Food intake of individuals with and without diabetes across different countries and ethnic groups. *Eur J Clin Nutr* 2011; 65: 635-641
24. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. *Epidemiology* 2003; 14: 479-487
25. Vart P, Gansevoort RT, Coresh J, Reijneveld SA, Bultmann U. Socioeconomic measures and CKD in the United States and The Netherlands. *Clin J Am Soc Nephrol* 2013; 8: 1685-1693
26. Silverwood RJ, Pierce M, Hardy R et al. Low birth weight, later renal function, and the roles of adulthood blood pressure, diabetes, and obesity in a British birth cohort. *Kidney Int* 2013; 84: 1262-1270
27. Mackenbach JP, Karanikolos M, McKee M. The unequal health of Europeans: successes and failures of policies. *Lancet* 2013; 381: 1125-1134
28. Moskvina V, Smith M, Ivanov D et al. Genetic differences between five European populations. *Hum Hered* 2010; 70: 141-149
29. Stel VS, Kramar R, Leivestad T et al. Time trend in access to the waiting list and renal transplantation: a comparison of four European countries. *Nephrol Dial Transplant* 2012; 27: 3621-3631
30. Vanholder R, Davenport A, Hannedouche T et al. Reimbursement of dialysis: a comparison of seven countries. *J Am Soc Nephrol* 2012; 23: 1291-1298
31. Janssen KJ, Vergouwe Y, Kalkman CJ, Grobbee DE, Moons KG. A simple method to adjust clinical prediction models to local circumstances. *Can J Anaesth* 2009; 56: 194-201
32. Toll DB, Janssen KJ, Vergouwe Y, Moons KG. Validation, updating and impact of clinical prediction rules: a review. *J Clin Epidemiol* 2008; 61: 1085-1094

TABLES

Table 1: Validated RRT survival prediction model as published in BMC Nephrology⁸

Patient characteristics	Parameter estimate*
Age (per year)	0.054
Primary renal disease	
Glomerulonephritis	<i>Reference</i>
Cystic kidney disease	-0.280
Renal vascular disease	0.331
Diabetes	0.767
Other diseases	0.407
Unknown	0.296
Therapy at 90 days	
Hemodialysis	<i>Reference</i>
Peritoneal dialysis	-0.131
Kidney transplantation	-1.634
Male sex	0.067
Baseline hazards	
1 year	0.003
3 year	0.010
5 year	0.017
7 year	0.024
10 year	0.033

* prognostic index of a patient: the sum of (the product of) parameter estimates

The survival probability at a certain time point, $S(t)$ can be calculated from the prognostic index and the baseline hazard, using the following equation: $S(t)=\exp(-H_0(t)*\exp(\text{prognostic index}))$.

E.g. a male 55 year old patient with Diabetes, that started on HD has a prognostic index of $((55 \text{ year} * 0.054=2.97)+0.767 \text{ (PRD diabetes)} +0.067 \text{ (male)})=3.804$;

The 10-year survival prognosis is: $\exp(-0.033*(\exp(3.804)))= 23\%$

Table 2: Distribution of prediction variables in ERA-EDTA Registry validation cohort; countries (random order) and total external validation cohort, compared to the development cohort⁸

Country	A	B	C	D	E	F	G	H	I	J	Total validation cohort	Development cohort ⁸
Age group %												
16-45	14.5	10.9	17.2	15.2	19.2	11.3	12.5	19.3	14.5	19.3	15.1	17.6
45-65	39	30.1	38	33.2	41.3	28	31.1	33.8	33.3	34.3	33.4	36.9
65-75	27.9	30.5	27.1	31.1	26.7	28	34.6	25	26.6	26.9	29.3	28.4
75+	18.6	28.5	17.6	20.5	12.8	32.8	21.8	21.9	25.5	19.6	22.2	17.2
PRD %												
Glomerulonephritis	14.4	11.9	12.3	14.6	14.5	14.1	15.1	21.5	16.2	13.7	14.4	12.5
Cystic kidney disease	4.5	5.4	6.5	7.3	9.3	7.1	5.1	8.9	6.3	7.2	6.6	8.8
Renal vascular disease	16.2	22.7	13.1	17.4	5.8	24.5	12.2	25.2	10.9	11.7	15.8	25.2
Diabetes	32.1	22.8	23.2	19.1	34.4	21.9	25.4	13.5	24.6	19.8	22.6	16.6
Other diseases	21.7	28.8	24.8	20.4	24.8	22.5	14.9	27	31.1	25.8	23.4	21.8
Unknown	11.1	8.4	20.1	21.1	11.2	10	27.2	3.9	10.9	21.8	17.2	14.9
Therapy at 90 days (%)												
Hemodialysis	88.7	86.9	64.5	86.7	70.5	81.7	88	68.6	64.1	65.3	78.5	65.5
Peritoneal dialysis	9	11.6	31.6	11.9	28.3	15.7	11.4	17.9	31.8	31.8	19.1	31.7
Transplantation	2.3	1.5	3.9	1.5	1.2	2.6	0.6	13.5	4.1	3	2.5	2.8
Sex, % male	60.5	58.1	63.1	61.3	62.5	60.9	61.5	67	64.3	61.1	61.4	61.1

Table 3: Stratified calibration and discrimination results

	N	CALIBRATION									DISCRIMINATION			
		PRED 3Y surv.	OBS 3Y surv.	Diff. 3Y surv.	PRED 5Y surv.	OBS 5Y surv.	Diff. 5Y surv.	PRED 10Y surv.	OBS 10Y surv.	Diff. 10Y surv.	C-index	CI-low	CI-high	

Age group														
16-45	20659	0.913	0.909	0.35%	0.856	0.865	-0.98%	0.744	0.778	-3.34%	0.701	0.694	0.708	
45-65	45507	0.736	0.752	-1.59%	0.597	0.625	-2.82%	0.389	0.422	-3.27%	0.660	0.657	0.663	
65-75	39901	0.514	0.560	-4.61%	0.325	0.366	-4.07%	0.126	0.122	0.44%	0.572	0.569	0.575	
75-100	30235	0.342	0.413	-7.13%	0.166	0.207	-4.08%	0.038	0.031	0.63%	0.551	0.547	0.554	
Sex														
F	52674	0.611	0.645	-3.39%	0.462	0.496	-3.35%	0.290	0.306	-1.63%	0.710	0.707	0.713	
M	83630	0.610	0.644	-3.46%	0.460	0.491	-3.13%	0.287	0.301	-1.37%	0.710	0.708	0.712	
Starting year RRT														
1995	7200	0.656	0.646	0.96%	0.512	0.500	1.23%	0.334	0.311	2.30%	0.727	0.720	0.734	
1996	7515	0.644	0.644	-0.04%	0.498	0.499	-0.13%	0.320	0.301	1.85%	0.714	0.707	0.721	
1997	8541	0.646	0.648	-0.17%	0.501	0.493	0.79%	0.323	0.312	1.03%	0.714	0.708	0.721	
1998	9994	0.635	0.651	-1.64%	0.487	0.494	-0.65%	0.310	0.300	0.97%	0.716	0.710	0.722	
1999	10565	0.629	0.646	-1.71%	0.481	0.493	-1.23%	0.304	0.307	-0.25%	0.712	0.705	0.718	
2000	11372	0.620	0.635	-1.54%	0.471	0.486	-1.57%	0.295	0.297	-0.22%	0.712	0.706	0.718	
2001	12283	0.609	0.641	-3.25%	0.459	0.485	-2.56%	0.286	0.293	-0.71%	0.710	0.704	0.715	
2002	14394	0.602	0.634	-3.17%	0.452	0.489	-3.71%	0.279	0.307	-2.78%	0.715	0.709	0.720	
2003	15814	0.594	0.643	-4.90%	0.443	0.490	-4.74%	0.272	0.301	-2.90%	0.709	0.704	0.714	
2004	18464	0.587	0.646	-5.96%	0.436	0.492	-5.58%	0.267	0.295	-2.73%	0.707	0.702	0.712	
2005	20162	0.580	0.653	-7.34%	0.428	0.504	-7.57%	0.261	0.331	-6.99%	0.705	0.701	0.710	

PRED=predicted, OBS = observed, Diff.=difference, 3Y/5Y/10Y= 3/5/10 year, CI-low = confidence interval lower limit, CI-high = confidence interval higher limit

Legends to figures:

Figure 1: calibration plots for 10-, 5- and 3-year survival per decile of predicted survival for the complete ERA-EDTA Registry cohort

Figure 2: calibration in the large for 10-, 5- and 3-year survival per country, sorted by overall performance (high-low)

Figure 3: discrimination (C-index) outcomes for 10-year survival per country (sorted like figure 2)

FIGURES






Figure 1: calibration plots for 10-, 5- and 3-year survival per decile of predicted survival for the complete ERA-EDTA Registry cohort

10-year observed and predicted survival probabilities per country



5-year observed and predicted survival probabilities per country






Figure 2: calibration in the large for 10-, 5-, and 3-year survival per country, sorted (different from table 2) by overall performance (high-low; “overall performance” is the average performance over the 3 periods of time)




Figure 3: discrimination (C-index) outcomes for 10-year survival per country (sorted like figure 2)